COMMUNIQUÉS West-GlobeNewswire

Zevra Therapeutics to Present at the Citizens Life Sciences Conference
25/02/2026
CELEBRATION, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, [...]
Effective Oral Steroids For Strength & Muscle Growth 2026: Legal Steroids For Sale" Smart Bodybuilders Use Crazy Bulk Steroid Alternatives.
25/02/2026
Legal Steroids For Sale 2026: Launched By Crazy Bulk" Steroids Alternatives for Cutting, Bulking, Body Building & Muscle Growth Safe Oral Steroids For Strength in USA. New York City, Feb. 25, 2026 (GLOBE NEWSWIRE [...]
Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria
25/02/2026
Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSU Topline data expected Q4 2026 BLA submission planned for 2027 HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE [...]
Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
25/02/2026
Achieved $48 million and $184 million in RYTELO ® (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025, within the previous [...]
Upstream Bio to Participate in Upcoming March Investor Conferences
25/02/2026
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today [...]
Aquestive Therapeutics to Participate in Upcoming March Investor Conferences
25/02/2026
WARREN, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026
25/02/2026
WATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal [...]
Axsome Therapeutics to Participate in Upcoming Investor Conferences
25/02/2026
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it [...]
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
25/02/2026
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies [...]
Tonix Pharmaceuticals to Participate in Two Investor Conferences in March
25/02/2026
BERKELEY HEIGHTS, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced that the [...]
ICPO Foundation and the World Federation of Nuclear Medicine and Biology (WFNMB) cooperate to advance Theranostics worldwide
25/02/2026
The strategic partnership will also support the WHO resolution WHA78.13 with the aim to improve access to medical imaging and nuclear medicine February 25, 2026 – Wiesbaden, Germany. The International Centers for [...]
RYBREVANT®▼ (amivantamab) par voie sous-cutanée, approuvé par la Commission Européenne pour une administration toutes les trois ou quatre semaines chez les patients atteints d’un cancer du poumon non à petites cellules avancé avec mutations de l’EGFR
25/02/2026
L’amivantamab sous-cutané (SC) réduit l’administration de plusieurs heures à quelques minutes, avec une efficacité et une sécurité comparables à celles de l’amivantamab intraveineux (IV) 1 ,2,3,4,5 L’amivantamab SC est [...]
Helsinn Healthcare & InVirtuoLabs sign a Strategic Collaboration in AI-Driven Drug Discovery
25/02/2026
Partnership combines Helsinn proprietary compound library with InVirtuoLabs generative AI platform to accelerate discovery of novel therapeutics Lugano, Switzerland – February 25, 2026 – Helsinn Healthcare SA (Helsinn [...]
Synklino announces publication in American Journal of Transplantation highlighting proof-of-concept for SYN002 in eliminating CMV in human kidneys
25/02/2026
Preclinical data demonstrate >90% reduction in human cytomegalovirus (HCMV) reactivation from latency, establishing proof-of-concept for SYN002 in human kidneys Data published in the American Journal of [...]
Novonesis delivered strong organic sales growth of 7% in 2025
25/02/2026
COPENHAGEN, Denmark – February 26, 2026. Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall. Ester [...]
Incentive programs for the Executive Leadership Team, the Senior Leadership Team and directors, and other employees
25/02/2026
Please read the full announcement in PDF Attachment 2026_02_LTI
Ethris Part of Consortium to Receive up to EUR 148 Million European Commission Contract to Advance Novel Pandemic Influenza Vaccine
25/02/2026
Initial tender contract of EUR 13 million supports gated advancement into two subsequent competitive phases MUNICH, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Ethris GmbH , a clinical-stage biotechnology company pioneering next- [...]
35Pharma to be Acquired by GSK to Accelerate Development of HS235, a Potential Best-in-Class Investigational Medicine for Pulmonary Hypertension (PH)
25/02/2026
Acquisition includes HS235, a potentially best-in-class activin signalling inhibitor in clinical development for treatment of cardiopulmonary diseases HS235 offers potential to treat pulmonary hypertension (PH) patients [...]
Novonesis' Annual Report 2025
25/02/2026
Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year overall. Ester Baiget, President & CEO: ”In 2025, we [...]

Pages